Top

Published in:

Open Access 01-12-2013 | Case report

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F

Authors: Friederike Pastore, Stephanie Schneider, Oliver Christ, Wolfgang Hiddemann, Karsten Spiekermann

Published in: Experimental Hematology & Oncology | Issue 1/2013

Abstract

We present a case of a 42-year old female with the rare diagnosis of a myeloproliferative syndrome harboring both a BCR-ABL transclocation and a JAK2V617F mutation.

Initially diagnosed with a CML, the patient underwent treatment with imatinib followed by dasatinib. Despite a major molecular response, the patient developed a thrombocytosis. Molecular analyses revealed a heterozygous JAK2V617F mutation, which was detected retrospectively in the bone marrow at the time of CML diagnosis.

This case underlines the complexity of MPS pathogenesis. For the clinician, a JAK2 mutational screening should be performed in CML patients without hematological response in the absence of BCR-ABL.

Available only for authorised users

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F: Prognostic discrimination in “good-risk” chronic granulocytic leukemia. blood 1984, 63: 789–799.PubMed

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon Alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst 1998, 90: 850–858. 10.1093/jnci/90.11.850PubMedCrossRef

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia Vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366: 1945–1953. 10.1016/S0140-6736(05)67785-9PubMedCrossRef

Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352: 1779–1790. 10.1056/NEJMoa051113PubMedCrossRef

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005,7(4):387–397. 10.1016/j.ccr.2005.03.023PubMedCrossRef

James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005,434(7037):1144–1148. 10.1038/nature03546PubMedCrossRef

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott M, Erber WN, Green AR: Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005,365(9464):1054–1061.PubMedCrossRef

Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa J-PJ: blood. 2005, 106: 3370–3373. 10.1182/blood-2005-05-1800PubMedCentralPubMedCrossRef

Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR: The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. blood 2005, 106: 2920–2921. 10.1182/blood-2005-05-2087PubMedCrossRef

10.

Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, Defina M, Bosi A, Francesco L: Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007, 8: 864–866. 10.1016/S1470-2045(07)70295-4PubMedCrossRef

11.

Pingali SRK, Mathiason MA, Lovrich SD, Go RS: Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 2009, 9: E25-E29. 10.3816/CLM.2009.n.080PubMedCrossRef

12.

Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, Albano F, Fava C, Vannucchi AM: Concomitant occurrence of BCR-ABL and JAK2V617F mutation. blood 2011, 118: 3445–3446. 10.1182/blood-2011-07-365007PubMedCrossRef

13.

Curtin NJ, Campbell PJ, Green AR: The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005, 128: 734–736. 10.1111/j.1365-2141.2005.05396.xPubMedCrossRef

14.

Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud J-P, Ffrench M: Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008, 32: 1608–1610. 10.1016/j.leukres.2008.03.004PubMedCrossRef

15.

Tefferi A, Levitt R, Lasho TL, Knudson RA, Ketterling RP: Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol 2010, 85: 86–87.PubMed

16.

Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K: Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007, 21: 1103–1104.PubMed

17.

Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, Cross NC, Jones AV, Ho AD, Hensel M: JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007,8(7):658–660. 10.1016/S1470-2045(07)70206-1PubMedCrossRef

18.

Nadali F, Ferdowsi Sh, Karimzadeh P, Chahardouli B, Einollahi N, Mousavi SA, Bahar B, Dargahi H, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH: JAK2–V617F Mutation and Philadelphia Positive Chronic Myeloid Leukemia. IJHOSCR 2009,3(3):43–45.

19.

Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH: Myelofibrosis evolving during Imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. blood 2007, 109: 4106–4107.PubMedCrossRef

20.

Pahore Z-A-A, Shamsi TS, Taj M, Farzana T, Ansari SH, Nadeem M, Ahmad M, Naz A: JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression. J Coll Physicians Surg Pak 2011, 21: 472–475.PubMed

21.

Nadali F, Sh F, Karimzadeh P, Chahardouli B: JAK2-V617F Mutation and Philadelphia positive chronic myeloid leukemia. IJHOSCR 2009,3(3):43–45.

22.

Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A: JAK2 Germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leuk 2010, 24: 105–109. 10.1038/leu.2009.225CrossRef

23.

Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC: Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. blood 2009, 113: 2022–2027. 10.1182/blood-2008-07-167056PubMedCrossRef

24.

Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. blood 2010, 115: 2003–2007. 10.1182/blood-2009-09-245381PubMedCrossRef

25.

Bumm T, Müller C, Al-Ali H-K, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MWN: Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. blood 2003, 101: 1941–1949. 10.1182/blood-2002-07-2053PubMedCrossRef

26.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval J-L: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. blood 2006, 108: 1652–1660. 10.1182/blood-2006-02-002030PubMedCrossRef

27.

Tefferi A, Pardanani A: Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 2006, 30: 739–744. 10.1016/j.leukres.2006.01.004PubMedCrossRef

Title: Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
Authors: Friederike Pastore
Stephanie Schneider
Oliver Christ
Wolfgang Hiddemann
Karsten Spiekermann
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/2162-3619-2-24

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)

Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis

The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma

CD133: a stem cell biomarker and beyond

Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer